Nanoliposomes (NLs) hold promise as new highly specific nanomedicine for anti-tumor vaccines, since they could be targeted to specific receptors on dendritic cell (DC) to induce maturation and activation and increase the anti-tumor immune response. Here we studied a NLs formulation targeted or not to FcR (the receptor for the IgG Fc fragment) for the treatment of androgen-responsive prostate cancer. Luteinizing-hormone-releasing hormone (LHRH) peptide (B- and T-cell epitopes), in tandem with a tetanus toxoid T-helper epitope (830-844 region) and several TLR (Toll-Like Receptor) ligands as adjuvants were co-encapsulated. Specific uptake in vitro of LHRH-TT liposomes targeted to the FcRs of human DCs was enhanced. DC maturation/activation, cytokine production and lymphocyte activation were consistently higher in targeted than non-targeted liposomes. Similar increase was observed as more adjuvants were administrated. Targeting to specific receptor and co-encapsulation of several TLR adjuvants are essential factors for the immune response in peptide based liposome vaccine.

Additional Metadata
Keywords Cancer vaccines, Delivery system, Dendritic cells, Immunotherapeutic vaccines, Peptide vaccines, Targeting
Persistent URL dx.doi.org/10.1016/j.imbio.2017.06.002, hdl.handle.net/1765/100566
Journal Immunobiology
Citation
Rueda, F. (Felix), Eich, C, Cordobilla, B. (Begoña), Domingo, P, Acosta, G. (Gerardo), Albericio, F. (Fernando), … Domingo, J.C. (Joan C.). (2016). Effect of TLR ligands co-encapsulated with multiepitopic antigen in nanoliposomes targeted to human DCs via Fc receptor for cancer vaccines. Immunobiology. doi:10.1016/j.imbio.2017.06.002